Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer

#MRKR Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

www.stocktitan.net/news/MRKR/marker-therape...

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company with the worldwide exclusive license of Multi-Antigen Targeted T cells

#MRKR Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology

www.stocktitan.net/news/MRKR/good-morning-a...

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer Marker Therapeutics (Nasdaq: MRKR) announced publication of Baylor College of Medicine clinical data showing a favorable safety profile and an 84.6% disease control rate in Arm A when Multi-Antigen Targeted T cells were combined with frontline chemotherapy in pancreatic ductal adenocarcinoma.Key metrics: median duration of response 7.5 months (range 3.5–16.6) for responders and median overall survival 14.1 months. Infused T cells persisted at detectable levels 12 months post-treatment and higher frequencies correlated with clinical response. Marker says it plans to start its pancreatic program in H1 2026 and has secured non-dilutive NIH SBIR and CPRIT funding to support the program.

#MRKR Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

www.stocktitan.net/news/MRKR/baylor-college...

Charts of the Day - small-cap stocks forming rising three methods candlestick signal, Mon Dec 29th - #AIRJ #MRKR - More: crystalequityresearch.com/charts-of-th... - #smallcap

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates Marker Therapeutics (NASDAQ: MRKR) reported Q3 2025 results and program updates on Nov 14, 2025. Key clinical highlights include a 66% objective response rate and 50% complete response rate for MT-601 in relapsed NHL from the Phase 1 APOLLO study (8/12 ORR; 6/12 CR), with five responses ≥6 months and three ≥12 months. No DLTs or ICANS observed. The company treated the first patient in its Off-the-Shelf RAPID study and signed a cGMP manufacturing collaboration with Cellipont. Marker raised approximately $10.0 million via ATM; cash and restricted cash totaled $19.0 million at 9/30/25, funding operations into Q3 2026 under current assumptions.

#MRKR Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/MRKR/marker-therape...

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data consistent with other MAR-T cell studies HOUSTON, Oct. 06, 2025 (GLOBE NEWSWIRE)

#MRKR Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

www.stocktitan.net/news/MRKR/marker-therape...

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma Marker Therapeutics (NASDAQ:MRKR) has reported encouraging results from its Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing T cell product, for treating relapsed lymphoma. The study demonstrated a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with 50% achieving complete response.The trial included 24 B-cell lymphoma patients across 7 U.S. clinical sites, with doses ranging from 100x106–400x106 cells. Notable outcomes include 78% objective response rate in Hodgkin Lymphoma patients and durable responses lasting 3-24 months. The treatment showed a favorable safety profile with no dose-limiting toxicities or serious adverse events.The company is advancing to the dose expansion phase, investigating MT-601 at the maximum dose of 400x106 cells in DLBCL patients who have relapsed after or are ineligible for CAR-T therapy.

#MRKR Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

www.stocktitan.net/news/MRKR/marker-therape...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Tue Jul 8th - #ULCC #RAPT #PRTA #MRKR #LTBR #KIRK #IKNA #GLRE #FDMT #EVAX #ONTH #STAA #TVNA #BLFS #BRCP #AYTU #ZEPP #VLRS #SEMR #OBK #LUXE #HBI #CHCG #REPL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Breakthrough: Marker's Cancer Treatment Achieves 78% Response Rate in Lymphoma Patients After CAR-T Failure New clinical data reveals enhanced T-cell therapy effectiveness through lymphodepletion in resistant lymphoma patients. See complete response rates and safety profile.

#MRKR Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

www.stocktitan.net/news/MRKR/marker-therape...

Leading Cancer Experts Reveal How MAR-T Technology Could Revolutionize CAR-T Cell Therapy Limitations Top oncology experts discuss groundbreaking MAR-T cell therapy approach to overcome CAR-T limitations. Join virtual panel with Baylor, City of Hope leaders. Register now.

#MRKR Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

www.stocktitan.net/news/MRKR/marker-therape...

Breakthrough: Marker's Lymphoma Drug Shows 78% Success Rate as Company Raises $29M Latest clinical data reveals 78% response rate in lymphoma patients with MT-601 therapy. Company strengthens position with $29.1M funding, extending operations through 2026.

#MRKR Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

www.stocktitan.net/news/MRKR/marker-therape...

NEWS: ( NASDAQ: #MRKR ) Equal-Weight Recommendation Issued On MRKR By Barclays

Breaking News: ( NASDAQ: #MRKR ) Buy Recommendation Issued On MRKR By Canaccord Genuity

JUST IN: ( NASDAQ: #MRKR ) Outperform Recommendation Issued On MRKR By Oppenheimer

Marker Therapeutics Secures $16.1M Private Placement to Advance Lymphoma Cell Therapy Trial Marker Therapeutics raises significant funding from top healthcare investors to accelerate Phase 1 APOLLO study of MT-601 for lymphoma patients post CAR-T therapy.

#MRKR Marker Therapeutics Announces $16.1 Million Private Placement

www.stocktitan.net/news/MRKR/marker-therape...

Marker Therapeutics' MT-601 Shows 78% Response Rate in Lymphoma Trial, Promising Post-CAR-T Results Phase 1 APOLLO study reveals strong efficacy with 44.4% complete response in lymphoma patients who failed CAR-T therapy. MT-601 demonstrates robust safety profile.

#MRKR Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

www.stocktitan.net/news/MRKR/marker-therape...

BREAKING NEWS: ( NASDAQ: #MRKR ) Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

#StockMarket #News

#MRKR Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

www.stocktitan.net/news/MRKR/marker-therape...

#MRKR Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

www.stocktitan.net/news/MRKR/marker-therape...

JUST IN: ( NASDAQ: #MRKR ) Marker Therapeutics Inc. (NASDAQ: MRKR) Leading the Way in Wednesday Trading Based on Percentage Gain

#StockMarket #News